| INTRODUCTION
Chronic hepatitis C virus (HCV) infection can be responsible for cirrhosis, hepatocellular carcinoma (HCC), end-stage liver diseases and other complications such as oesophageal varices and portal hypertension. 1, 2 With the rapid development of direct-acting anti-virals (DAAs), HCV treatment has become much easier than ever because of the short-term and well-tolerated treatment regimens. Recent studies in real-life clinical practice, including ours, reported that the rates of sustained viral response (SVR) exceeded 90% for both HCV genotypes 1 and 2 in treatment with sofosbuvir (SOF) plus ledipasvir (LDV) or SOF plus ribavirin (RBV). [3] [4] [5] [6] [7] Sustained viral response by interferon-based treatment is associated with the regression of hepatic fibrosis, 8 health-related quality of life, 9 and reduced occurrence of HCC 10, 11 or liver-related morbidity and mortality. 11 While no evidence exists regarding the long-term effects after achieving SVR by DAAs, it contributes to improvements in the biochemical parameters of liver function 12 and health-related quality of life 13 shortly after treatment. In contrast, recent reports have highlighted the significant impact of early HCC recurrence (27.6%-28.8%), within about 24 weeks. 14, 15 However, it remains controversial whether or not the early HCC development is related to the use of DAAs. 16 Japanese HCV patients characteristically are older than patients in Europe and the USA. 17 Advanced age has been proven to be an independent risk factor for the development of HCC, 10, 18 thus the percentage of Japanese who develop HCC would be expected to be higher than that in other countries. It remains to be clarified in a large study whether or not the early development of HCC is associated with DAA treatment. As much data as possible on this issue are urgently needed to better manage HCC surveillance in clinical practice, especially for older patients.
The purpose of this study was to evaluate the short-term (within 2 years) risk of HCC among Japanese patients with chronic HCV infection, including compensated cirrhosis and previous HCC, following the achievement SVR by SOF-based regimens for 12 weeks. We also identified baseline and on-treatment factors associated with HCC development by dividing the patients into groups with or without previous HCC.
| PATIENTS AND METHODS

| Patients
The Kyushu University Liver Disease Study (KULDS) Group Patients with previous HCC received anti-viral therapy at least 3 months after completing treatment for HCC.
A flow chart of the patient disposition is shown in Figure 1 . /L] 9 (alanine amino-
. 21 These assessments were performed within 1 month before the initiation of anti-viral treatment.
HCV RNA was measured using a real-time reverse transcriptase PCR assay (COBAS TaqMan HCV assay, Version 2.0) (Roche OGAWA ET AL.
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Molecular Diagnostics, Tokyo, Japan) that has a lower limit of quantitation of 15 IU/mL and an outer limit of quantitation of 6.9 9 10 7 IU/mL (1.2-7.8 log IU/mL referred to log 10 IU/mL).
SVR12 was categorised as undetectable HCV RNA (target not detected) at week 12 after the EOT.
The follow-up period reflects the time between the date of the last image assessment and the start date of SOF-based treatment.
We also registered the patient status as living or deceased at the end of March 2017.
| HCC surveillance
All patients were examined for HCC by abdominal ultrasonography, dynamic computed tomography and/or magnetic resonance imaging at baseline and every 3-6 months after the initiation of treatment.
Serum a-fetoprotein (AFP) was determined every 3 months for each patient. The surveillance protocols were in accordance with the Japanese standards of care. The main outcome was HCC incidence. Cumulative HCC incidence curves were plotted using the Kaplan-Meier method.
| Statistical analysis
Differences among groups were assessed using the log-rank test.
Risk factors associated with HCC development were determined by the Cox proportional hazard model. Multivariable models were constructed by considering all variables with P < .10 in univariate analysis in a stepwise backward selection approach. Hazard ratios (HR) and their 95% confidence interval (CI) were generated by Cox proportional hazard model. Area under the receiver operating characteristic curve (AUROC) analysis was done to evaluate the relation between AFP and HCC occurrence. The cut-off value was selected from the receiver operating characteristic (ROC) curve to maximise the total sensitivity and specificity. P < .05 was regarded as statistically significant in all analyses.
3 | RESULTS
| Patient characteristics
Demographic and baseline characteristics are shown in Table 1 . The median age was 66 years (range, 20-91). Approximately 44% were male, 68% were treatment-na€ ıve and 22% had cirrhosis. One hundred and fifty-two (9.1%) patients had completed treatment for HCC at least 3 months before the initiation of DAA treatment. Age, AFP level and the percentages male, with diabetes, with cirrhosis, HCV genotype 1, and treatment experienced in the previous HCC group were significantly higher than in nonprevious HCC group. The serum albumin level and platelet count of the previous HCC group were significantly lower than that of the nonprevious HCC group.
Characteristics of patients with previous HCC are shown in Figure 2A ,B respectively. The cumulative de novo HCC of the noncirrhosis group was significantly lower than that of the cirrhosis group (log-rank test: P < .001). The 1-year cumulative rates of de novo HCC were 0.4% and 4.9% for the noncirrhosis and cirrhosis groups respectively. In contrast, the cumulative HCC recurrence of the noncirrhosis group was significantly lower than that of the cirrhosis group (log-rank test: P = .023). The 1-year cumulative HCC recurrence rates were 6.5% and 23.1% for the noncirrhosis and cirrhosis groups respectively. Moreover, we analysed the factors associated with de novo HCC separately by cirrhosis status (noncirrhosis : Table S1 , cirrhosis: Table S2 ). For noncirrhosis patients, lower platelet count and advanced fibrosis were associated with de novo HCC (P = .028 and P = .016 respectively). The Kaplan-Meier curves for de novo HCC classified by fibrosis status (advanced and no/mild fibrosis groups) are shown in Figure 3A . The cumulative de novo HCC of the advanced fibrosis group was significantly higher than that of the no/ mild fibrosis group (log-rank test: P = .010). However, the 1-year cumulative rates of de novo HCC were only 0.1% and 1.2% for the no/mild and advanced fibrosis groups respectively. Otherwise, EOT-AFP level (by every 1 ng/mL) (HR 1.10, 95% CI 1.04-1.17, P = .0028) was extracted as predictive of de novo HCC for cirrhotic patients in multivariable Cox analysis. ROC curve analysis was performed to determine the optimal threshold value of EOT-AFP level for predicting de novo HCC, and the cut-off value for EOT-AFP was 9.0 ng/mL (sensitivity 78.6%, specificity 69.7%, AUROC 0.76). The
| Factors associated with de novo HCC
Kaplan-Meier curves for de novo HCC classified by cut-off EOT-AFP level are shown in Figure 3B . The cumulative de novo HCC of the EOT-AFP <9.0 ng/mL group was significantly lower than that of the EOT-AFP ≥9.0 ng/mL group (log-rank test: P < 0.001). The 1-year cumulative de novo HCC rates were 1.4% and 13.1% in the EOT-AFP <9.0 ng/mL and ≥9.0 ng/mL groups respectively. Figure S1A ,B respectively. Moreover, we showed the KaplanMeier curves for HCC recurrence classified by these 2 factors combined in Figure S2 . The cumulative HCC recurrence rate was significantly higher for the noncurative/<1 year group than for the other 3 groups by pairwise comparison with log-rank test. Both of the patients in the previous HCC group who died had liverrelated complications, HCC recurrence (14 months) and liver failure (12 months). Noncurative procedures included transarterial chemoembolisation and radiotherapy.
| Factors associated with HCC recurrence
T A B L E 3 Factors associated with de novo HCC
control that allows tumour clones to emerge. 23 On the other hand, multicentre studies that included different study designs, baseline characteristics and treatment options for prior HCC do not support this finding. 16, 24, 25 In this study, the overall 1-year cumulative HCC recurrence rate was 16.5%, with a lower annual recurrence rate after resection or percutaneous ablation. 26 However, the 1-year cumulative HCC recurrence rate was 23.1% when limited to cirrhotic patients. Previously, we reported on HCC recurrence after treatment with pegylated-interferon alpha plus RBV, finding a 1-year cumulative HCC recurrence rate of 22.2%, 27 with no significant difference between treatment with interferon and DAAs. We were not able to provide a new perspective because of differences in the agecomposition of the treatment option groups (interferon median age, 57: interferon-free DAA median age, 66), which made it difficult to analyse the data with propensity-score matching. Moreover, selection bias was an important consideration because of the fact that DAAs allow patients who in the past would never qualify for interferon therapy to be treated. A prospective cohort in comparison with untreated patients showed no evidence of an increased risk of early HCC recurrence in DAA treatment. 16 Although it is conceivable that the anti-viral treatment options are not associated with the HCC recurrence seen in our study, further studies will be necessary to better elucidate the relation. will be necessary to determine the potential long-term benefits related to the development of HCC and mortality.
The limitations of our study include factors related to its observational, real-life design, including potential physician prescribing bias and incomplete patient records. However, over 99% of the data for all items, except for EOT-AFP level (91.3%) and IL28B genotype (77.8%), were available in this study, and there were only 3 patients lost to follow-up. Taken together, our analysis was done from highly precise data that gives important insights into the risk of HCC development in a diverse patient population managed in clinical practice.
Another limitation is the lack of data on decompensated cirrhosis patients because they are not covered by public insurance in Japan, which may have contributed to the relatively low rate of HCC inci-
dence. An advantage is that many elderly patients were included in this study because the age of HCV-infected patients is increasing in Japan. Our findings will be useful for HCV management in other countries, with a similar trend forecast in Europe and the USA. 32 In conclusion, our data showed no evidence of an increased risk of de novo HCC or recurrence by patients treated with interferonfree SOF-based regimens. However, cirrhosis was strongly associated with the short-term development of HCC after HCV eradication. Moreover, our findings underscore the fact that the serum EOT-AFP level is a useful marker for predicting de novo HCC for cirrhotic patients and that close HCC surveillance should be required for patients with a past history of HCC, especially for patients treated with noncurative procedures. Going forward, further studies will be required to elucidate the risk of HCC development over the long-term.
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